31,596
edits
Changes
Jump to navigation
Jump to search
no edit summary
*D<sub>1</sub> receptors are affected in mood disorders and stereotypes and manifest their post-synaptic inhibition in the limbic system. In mood disorders and stereotypies D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> receptors are all also affected.
*D<sub>1</sub> receptors are affected in mood disorders and stereotypes and manifest their post-synaptic inhibition in the limbic system. In mood disorders and stereotypies D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> receptors are all also affected.
*Dopamine is also important in the putative ‘seeking’ circuit, which is involved in reinforcement of search, exploratory and investigatory behaviours. Animals that have an enhancement of the ‘seeking’ system become immensely interested in what is around them and become excited when they anticipate the arrival of things that they want.
*Dopamine is also important in the putative ‘seeking’ circuit, which is involved in reinforcement of search, exploratory and investigatory behaviours. Animals that have an enhancement of the ‘seeking’ system become immensely interested in what is around them and become excited when they anticipate the arrival of things that they want.
*Two of the main metabolites of selegiline, L-amphetamine and L-methamphetamine may also play a role in its effects, however the extent to which this is the case is uncertain.
*Two of the main metabolites of selegiline, L-amphetamine and L-methamphetamine are also stimulants of brain activity and may play a role in its effects, however the extent to which this is the case is uncertain.
*A decrease in the concentration of catecholamines in the CNS and reduced level of neurotransmission are thought to be the pathogenesis behind the clinical signs associated with cognitive decline.
*A decrease in the concentration of catecholamines in the CNS and reduced level of neurotransmission are thought to be the pathogenesis behind the clinical signs associated with cognitive decline.
==Use==
==Use==
The main uses for selegiline are the treatment of fears and phobias, and cognitive decline where reduced dopamine levels are implicated [of the type that resembles dementia of the Alzheimer’s type, DAT]. Selegiline should be administered for a minimum of 4 weeks before a reliable evaluation of efficacy is possible.
The main uses for selegiline are the treatment of fears and phobias, and cognitive decline where reduced dopamine levels are implicated [of the type that resembles dementia of the Alzheimer’s type, DAT]. Selegiline should be administered for a minimum of 4-8 weeks before evaluating efficacy. If there is not a considerable improvement after this time an increased dose may be necessary or re-evaluation of cause of the behavioural problem. Before treatment with selegiline other causes of abnormal behaviour should be ruled out.
*Licensed [dog]
*Licensed [dog]